Skip to Main Content

Paper Details

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
Neurology
165
2017
Alemtuzumab, CARE, CDI, CDW, MS, RRMS, Thyroid disorder, alemtuzumab, patients, relapsing-remitting MS
Author NameAffiliation
Hans-Peter HartungFrom the Department of Neurology and Center for Clinical Neuroscience (E.H.), Charles University and General University Hospital in Prague, Montreal Neurological Institute, McGill University, Cleveland Clinic, OH Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Germany MS Clinic of Central Texas (E.J.F.), Round Rock Queen Mary University of London (G.G.), Barts and The London School of Medicine, University Hospital Zurich and University of Zurich, Medical University of Lodz, Poland The University of British Columbia (A.T.), University of Cambridge
Krzysztof SelmajFrom the Department of Neurology and Center for Clinical Neuroscience (E.H.), Charles University and General University Hospital in Prague, Montreal Neurological Institute, McGill University, Cleveland Clinic, OH Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Germany MS Clinic of Central Texas (E.J.F.), Round Rock Queen Mary University of London (G.G.), Barts and The London School of Medicine, University Hospital Zurich and University of Zurich, Medical University of Lodz, Poland The University of British Columbia (A.T.), University of Cambridge
  • 1 - 2

Datasets